Recital 4, Directive (EU) 2004/33

In forcesince 22 Mar 2004cited 1×

Blood and blood components imported from third countries, including those used as starting material/raw material for the manufacture of medicinal products derived from human blood and human plasma, should meet the quality and safety requirements set out in this Directive.

  • Opinion of Advocate General Mengozzi delivered on 17 July 2014. Geoffrey Léger v Ministre des Affaires sociales, de la Santé et des Droits dDecision

    Its adoption is part of a context in which the Member States had previously experienced failings in their systems for monitoring and securing the transfusion chain. Consequently, the supranational authorities took up the matter, at the …

    17 Jul 2014 · 62013CC0528